FSGS is hard and the data sucks. But here comes sparsentan fresh off its win in the PROTECT trial for IgA Nephropathy. Can it pull another rabbit out of the hat for patients that suffer from FSGS or are we doomed to forever treating our patients with Acthar® Gel?
Freely Filtered 68: Inpatient hypertension
Freely Filtered 67: NephMadness and Animal House
Freely Filtered 66: NephJC Summer Book Club
Freely Filtered 065: BEST Fluids
Freely Filtered 064: Freely Filtered with The Curbsiders Live at Kidney Week!
Freely Filtered 063: Late Breaking and High Impact Clinical Trial Simultaneous Release!
Freely Filtered 062: Inaxaplin for APOL1 Kidney Disease
Freely Filtered 061: Bicarb in Transplant
Freely Filtered 059: Furosemide v Torsemide
Freely Filtered 060: HCTZ v Kidney Stones, The NOSTONE trial
Freely Filtered 058: HCTZ v Chlorthalidone, The Diuretic Comparison Project
Freely Filtered 057: NephMadness 2023 TMA
Say "Hi" to the #NephMadness PodCrawl
The idea behind a podcrawl is for a variety of podcasts to coordinate on timing and topic to push a theme and get each other’s listeners to explore all of the podcasts. One of the first goals behind NephMadness was to build a community and in the early years of Twitter, NephMadness was central to the formation of #NephTwitter and defining the ethos that makes our online community kind, intelligent, vibrant, and interesting. The NephMadness Podcrawl hopes to inspire and grow the nephrology podcast community in the same way. For 2023, our second year, the PodCrawl has assembled the Avengers of Medical Pods!
Go to NephMadness.com/podcrawl for more information and links to all of the podcasts!